New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
10:25 EDTBSX, BSX, LLY, LLY, LH, LH, GEVA, GEVA, ACT, ACT, Q, Q, BIO, BIO, HSIC, HSIC, ALOG, ALOG, SIAL, SIAL, WMGI, WMGI, AGIO, AGIO, OPHT, OPHTJPMorgan to host a conference
32nd Annual Healthcare Conference is being held in San Francisco on January 13-16 with webcasted company presentations to begin on January 13 at 10:30 am; not all presentations may be webcasted. Webcast Link
News For OPHT;AGIO;WMGI;SIAL;ALOG;HSIC;BIO;Q;ACT;GEVA;LH;LLY;BSX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
December 8, 2014
11:30 EDTACTLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
10:42 EDTBSXOptions with increasing implied volatility
Subscribe for More Information
09:20 EDTAGIOOn The Fly: Pre-market Movers
Subscribe for More Information
08:10 EDTLLYLilly, Anthem, HealthCore form five-year research collaboration
Eli Lilly and Company (LLY), Anthem (ANTM) and HealthCore, Inc. announced that they have formed a five-year, real-world evidence research collaboration intended to improve health outcomes for patients. The companies will jointly develop and conduct research projects in health outcomes and real-world evidence in areas of mutual interest. Each party will bring distinct and valuable contributions to the collaboration, including the U.S. provider and patient environment, research capabilities, therapeutics and methods expertise, and integrated, researchable data. The collaboration allows the organizations to explore research opportunities across disease states and incorporate surveys and other information from providers and patients.
07:39 EDTAGIOAgios Pharmaceuticals volatility low into new data from Ongoing Phase 1 trial
Subscribe for More Information
07:36 EDTAGIOAgios announces Celgene to extend discovery phase of collaboration to April 2016
Agios Pharmaceuticals (AGIO) announced that Celgene (CELG) has elected to extend the period of its exclusivity for an additional year to April 2016 under the global strategic collaboration agreement. The two companies have been working together since April 2010 to discover, develop and commercialize disease-altering therapies in oncology arising from Agios' cancer metabolism research platform. The terms of the collaboration extension are consistent with previously agreed upon financial terms. As a result of the extension, Celgene will maintain its exclusive option to drug candidates that emerge from Agios' cancer metabolism research platform through April 2016. Agios will receive a $20M payment. Following this extension, the discovery portion of the collaboration will expire on April 14, 2016. Under the terms of the original agreement announced in April 2010, Agios leads research, preclinical and early development efforts through Phase 1, while Celgene receives an option to obtain exclusive rights either upon IND acceptance or at the end of Phase 1, to further development and commercialize medicines emerging from Agios' cancer metabolism research. Celgene would lead and fund global development and commercialization of some of these drugs, and Agios would retain development and commercialization rights for certain drugs in the United States. On all programs, Agios is eligible to receive up to $120M in milestone-based payments as well as royalties on any sales.
05:53 EDTBSXStocks with implied volatility movement; BSX BMY
Subscribe for More Information
December 7, 2014
16:40 EDTAGIOAgios announces new data from Ongoing Phase 1 trial of AG-221
Subscribe for More Information
14:14 EDTAGIOAgios Pharmaceuticals to hold a luncheon discussion
Investor Luncheon to review data presented at the American Society of Hematology's Annual Meeting is being held in San Francisco on December 8 at 3 pm. Webcast Link
14:10 EDTAGIOAmerican Society of Hematology to hold a meeting
Subscribe for More Information
December 5, 2014
16:49 EDTACTAdvisory Committee recommends approval Of Actavis' ceftazidime-avibactam
Actavis announced that the Anti-Infective Drugs Advisory Committee convened by the U.S. Food and Drug Administration has voted to recommend approval of Actavis' New Drug Application for ceftazidime-avibactam, an investigational antibiotic being developed to treat hospitalized patients when limited or no treatment options are available for complicated intra-abdominal infections and complicated urinary tract infections caused by Gram-negative pathogens. The committee found the scientific and clinical evidence submitted by Cerexa, a wholly owned subsidiary of Actavis, adequately demonstrated the safety and efficacy of ceftazidime-avibactam in the treatment of the proposed cIAI and cUTI indications. The committee voted not to recommend approval of the combination for hospital-acquired bacterial pneumonia /ventilator-associated bacterial pneumonia and bacteremia.The Advisory Committee recommendation is not binding on the FDA, which makes the final decision regarding approval. Actavis expects FDA action on its NDA for ceftazidime-avibactam during the first quarter of 2015.
12:31 EDTSIALSigma-Aldrich stockholders approve acquisition by Merck KGaA
Sigma-Aldrich (SIAL) stockholders voted to adopt the previously announced merger agreement providing for the acquisition of Sigma-Aldrich by Merck KGaA (MKGAY), Darmstadt, Germany at a special meeting of stockholders held earlier today. Sigma-Aldrich stockholders also approved, on an advisory, non-binding basis, compensation that may become payable to named executive officers as a result of the acquisition. As previously announced, on September 22, 2014, the board of directors for Sigma-Aldrich approved the merger agreement under which Merck KGaA, Darmstadt, Germany, will acquire Sigma-Aldrich for $140.00 per share in cash. The transaction, which is expected to close in mid-2015, remains subject to the satisfaction of the closing conditions set forth in the merger agreement, including regulatory approvals.
10:44 EDTBSXOptions with increasing implied volatility
Subscribe for More Information
07:01 EDTHSICHenry Schein announces $300M increase to share repurchase plan
Henry Schein announced that its board has authorized the repurchase of up to $300M of shares of the company's common stock. This program is in addition to the $300M repurchase program announced in December 2013, which as of today has approximately $10.5M remaining authorized for future repurchases.
05:54 EDTBSXStocks with implied volatility movement; BSX OPK
Stocks with implied volatility movement; Boston Scientific (BSX) 32, OPKO Health (OPK) 37 according to iVolatility.
December 4, 2014
17:09 EDTLHLabCorp files automatic mixed securities shelf
Subscribe for More Information
10:08 EDTAGIOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:33 EDTAGIOAgios Pharmaceuticals initiated with a Buy at MLV & Co.
Subscribe for More Information
07:56 EDTACTActavis price target raised to $315 from $266 at Morgan Stanley
Subscribe for More Information
07:05 EDTSIALSigma-Aldrich licenses foundational CRISPR patents from Boad Institute
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use